Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Placebo/sitagliptin 2x50 mg;   Drug: Canagliflozin 300 mg
Sponsor:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified March 2010

Condition:   GERD
Intervention:   Drug: esomeprazole 40 mg
Sponsors:   Digestive & Liver Disease Specialists;   AstraZeneca
Recruiting - verified March 2010

Condition:   Head Lice
Intervention:   Drug: Ivermectin Cream
Sponsor:   Topaz Pharmaceuticals Inc
Recruiting - verified February 2010

Condition:   Sarcoma
Interventions:   Biological: cixutumumab;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: irinotecan hydrochloride;   Drug: temozolomide;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Vaginosis, Bacterial;   Vaginal Infection
Interventions:   Drug: GW05;   Drug: GW05;   Drug: GW05;   Drug: Metronidazole
Sponsor:   Graceway Pharmaceuticals, LLC
Recruiting - verified March 2010

Condition:   Influenza
Interventions:   Drug: Oseltamivir;   Drug: Oseltamivir
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Ixabepilone;   Drug: Carboplatin
Sponsor:   US Oncology Research
Recruiting - verified February 2010

Condition:   Hypertriglyceridemia
Interventions:   Drug: AMR101 (ethyl icosapentate);   Drug: AMR101 (ethyl icosapentate);   Drug: Placebo
Sponsor:   Amarin Pharma Inc.
Recruiting - verified February 2010

Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Aclidinium bromide;   Drug: Aclidinium bromide;   Drug: Placebo
Sponsors:   Forest Laboratories;   Almirall, S.A.
Recruiting - verified February 2010

Conditions:   Diabetic Neuropathy, Painful;   Diabetic Polyneuropathy
Interventions:   Drug: tapentadol extended release (ER);   Drug: placebo
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Grünenthal GmbH
Recruiting - verified February 2010

Condition:   Hepatitis C, Chronic
Interventions:   Drug: Boceprevir (SCH 503034);   Drug: erythropoietin;   Biological: Peginterferon alfa-2b (SCH 54031);   Drug: Ribavirin (SCH 18908)
Sponsor:   Schering-Plough
Recruiting - verified March 2010

Condition:   Cervical Intraepithelial Neoplasia
Interventions:   Drug: RO5217790;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: taspoglutide;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773;   Drug: BI 10773;   Drug: BI 10773
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Onychomycosis
Interventions:   Drug: IDP-108;   Drug: Vehicle
Sponsor:   Dow Pharmaceutical Sciences
Recruiting - verified March 2010

Conditions:   Lymphoma;   Lymphoproliferative Disorder
Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sexual Dysfunctions, Psychological
Interventions:   Drug: Flibanserin;   Drug: Placebo
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Sexual Dysfunctions, Psychological
Interventions:   Drug: flibanserin;   Drug: placebo;   Drug: placebo
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Castrate-Resistant Prostate Cancer
Intervention:   Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsor:   Celgene Corporation
Recruiting - verified March 2010

Condition:   Coronary Artery Disease
Interventions:   Drug: Placebo & Aspirin;   Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
Sponsors:   Harvard Clinical Research Institute;   Abbott;   Boston Scientific Corporation;   Bristol-Myers Squibb;   Sanofi-Synthelabo;   Cordis Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.;   Medtronic
Recruiting - verified March 2010

Condition:   Castration-Resistant Prostate Cancer
Interventions:   Drug: MDV3100;   Drug: Placebo
Sponsor:   Medivation, Inc.
Recruiting - verified March 2010

Conditions:   Adenocarcinoma;   Advanced Breast Cancer;   Advanced Metastatic Breast Cancer;   ErbB2+;   Her2+;   Invasive Breast Cancer;   Metastatic ErbB2
Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Seasonal Influenza;   Cough;   Sore Throat;   Nasal Congestion;   Myalgia;   Headache;   Fatigue
Interventions:   Drug: Peramivir;   Drug: Peramivir
Sponsors:   BioCryst Pharmaceuticals;   Department of Health and Human Services
Recruiting - verified March 2010

Condition:   Hepatitis C
Intervention:   Drug: Infergen with or without ribavirin
Sponsor:   Three Rivers Pharmaceuticals
Recruiting - verified March 2010

Condition:   Low Back Pain
Interventions:   Biological: Tanezumab 20 mg;   Biological: Tanezumab 10 mg
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Hypertriglyceridemia;   Diabetic Neuropathy
Intervention:   Drug: omega-3-acie ethyl esters
Sponsors:   Eastern Virginia Medical School;   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Overactive Bladder
Interventions:   Drug: Fesoterodine;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Atrial Fibrillation;   Arrhythmia;   Stroke Prevention;   Mortality
Interventions:   Device: Left atrial ablation;   Drug: Rate or Rhythm Control Therapy
Sponsors:   Mayo Clinic;   National Heart, Lung, and Blood Institute (NHLBI);   Duke University;   St. Jude Medical;   Biosense Webster, Inc.
Recruiting - verified February 2010

Condition:   Alzheimer's Disease
Interventions:   Drug: LY2062430;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Genetic: loss of heterozygosity analysis;   Other: cytology specimen collection procedure;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Neoplasm of Uncertain Malignant Potential;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Other: cytology specimen collection procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Nonneoplastic Condition
Interventions:   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Intervention:   Drug: Sipuleucel-T
Sponsor:   Dendreon
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: docetaxel;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: cyclophosphamide;   Drug: pegfilgrastim
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Genentech;   US Oncology Research
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: systemic chemotherapy;   Procedure: axillary lymph node dissection;   Procedure: neoadjuvant therapy;   Procedure: sentinel lymph node biopsy;   Procedure: therapeutic conventional surgery;   Procedure: ultrasound imaging
Sponsors:   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: eribulin mesylate;   Drug: ixabepilone
Sponsor:   Eisai Inc.
Recruiting - verified March 2010

Condition:   Low Back Pain
Interventions:   Biological: Tanezumab 20 mg IV;   Drug: Placebo for naproxen;   Biological: Tanezumab 10 mg IV;   Drug: Placebo for naproxen;   Biological: Tanezumab 5 mg IV;   Drug: Placebo for naproxen;   Biological: Placebo for tanezumab;   Drug: Naproxen;   Biological: Placebo for tanezumab;   Drug: Placebo for naproxen
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: Everolimus;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified February 2010

Condition:   Gastrointestinal Stromal Tumor (GIST)
Intervention:   Drug: imatinib mesylate
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Cardiovascular Disorder;   Diabetes Mellitus
Interventions:   Drug: ezetimibe (+) simvastatin;   Drug: Comparator: simvastatin 40 mg or atorvastatin 20 mg;   Drug: Comparator: rosuvastatin;   Drug: Comparator: atorvastatin 10 mg or simvastatin 20 mg
Sponsor:   Merck
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: Dasatinib;   Drug: Leuprolide Acetate (LHRH Analogue);   Procedure: Radical Prostatectomy
Sponsors:   Hoosier Oncology Group;   Bristol-Myers Squibb
Recruiting - verified February 2010

Conditions:   B-Cell Lymphoma;   B-Cell Leukemia
Intervention:   Drug: PCI-32765
Sponsor:   Pharmacyclics
Recruiting - verified July 2009

Conditions:   Smoking Cessation;   Smoking;   Tobacco Cessation
Interventions:   Biological: NicVAX vaccine;   Biological: Placebo vaccine
Sponsors:   Nabi Biopharmaceuticals;   National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2010

Conditions:   Adrenocortical Carcinoma;   Kidney Cancer;   Liver Cancer;   Neuroblastoma;   Retinoblastoma;   Sarcoma
Interventions:   Biological: cixutumumab;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
Recruiting - verified October 2009

Conditions:   Arthritis;   Osteoarthritis
Interventions:   Biological: tanezumab 10 mg;   Biological: tanezumab 5 mg;   Drug: naproxen;   Other: placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Osteoarthritis
Interventions:   Biological: tanezumab;   Biological: tanezumab;   Biological: tanezumab
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Metastatic Non-small Cell Lung Cancer
Interventions:   Drug: CS7017 tablets;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Daiichi Sankyo Inc.
Recruiting - verified March 2010

Conditions:   Atherosclerosis;   Cardiovascular Disease;   Coronary Heart Disease;   CV Risk
Interventions:   Drug: Darapladib;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin phosphate;   Drug: Comparator: Placebo
Sponsors:   Merck;   Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified March 2010

Condition:   Crohn's Disease
Interventions:   Drug: vedolizumab;   Other: Placebo
Sponsor:   Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010

Condition:   Ulcerative Colitis
Interventions:   Drug: vedolizumab;   Other: Placebo
Sponsor:   Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010

Conditions:   Phenylketonuria;   Hyperphenylalaninaemia
Intervention:   Drug: Sapropterin Dihydrochloride
Sponsor:   BioMarin Pharmaceutical
Recruiting - verified January 2010

Condition:   Carcinoid Syndrome
Interventions:   Drug: lanreotide;   Drug: placebo
Sponsors:   Tercica;   Ipsen
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Therapy-related Toxicity
Interventions:   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Crohn's Disease
Intervention:   Drug: Ustekinumab; CNTO1275
Sponsor:   Centocor, Inc.
Recruiting - verified March 2010

Conditions:   Rhinitis;   Allergic Conjunctivitis
Interventions:   Biological: 1.5 Amb a 1-U;   Biological: 6 Amb a 1-U;   Biological: 12 Amb a 1-U;   Biological: Placebo
Sponsor:   Schering-Plough
Recruiting - verified March 2010

Condition:   Prostatic Neoplasms
Intervention:  
Sponsors:   University of Washington;   Canary Foundation;   Early Detection Research Network
Recruiting - verified February 2010

Condition:   Neoplasms
Intervention:   Drug: BIBW 2992
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Advanced Breast Cancer
Interventions:   Drug: Dasatinib + Fulvestrant;   Drug: Fulvestrant
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Condition:   Sarcoma
Interventions:   Drug: cisplatin;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: zoledronic acid;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pancreatic Cancer
Interventions:   Drug: erlotinib hydrochloride;   Drug: gemcitabine hydrochloride;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
Sponsors:   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2189265;   Drug: Sitagliptin 100mg, 24 months;   Drug: Placebo solution;   Drug: Placebo tablet, 6 months;   Drug: Placebo tablet, 24 months;   Drug: Sitagliptin 100 mg, 18 months
Sponsors:   Eli Lilly and Company;   United BioSource Corporation;   Tessella Inc.;   Berry Consultants
Recruiting - verified March 2010

Condition:   Fibromyalgia
Intervention:   Drug: Treatment for Fibromyalgia
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Liver Cancer;   Neuroblastoma;   Ototoxicity;   Ovarian Cancer;   Sarcoma
Interventions:   Drug: sodium thiosulfate;   Procedure: examination
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Biological: Sipuleucel-T;   Biological: Sipuleucel-T;   Biological: Sipuleucel-T
Sponsor:   Dendreon
Recruiting - verified February 2010

Condition:   Transitional Cell Carcinoma of the Bladder
Interventions:   Drug: Dasatinib;   Procedure: Radical Cystectomy
Sponsors:   Hoosier Oncology Group;   Bristol-Myers Squibb
Recruiting - verified February 2010

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Dasatinib + Letrozole;   Drug: Letrozole
Sponsors:   Bristol-Myers Squibb;   US Oncology Research
Recruiting - verified February 2010

Condition:   Kidney Neoplasms
Interventions:   Drug: Axitinib (AG-013736);   Drug: Sorafenib
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Euvolemic Hyponatremia
Interventions:   Drug: lixivaptan;   Drug: placebo
Sponsors:   CardioKine Inc.;   Cardiokine Biopharma, LLC;   Biogen Idec
Recruiting - verified March 2010

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: Placebo;   Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor:   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Venous Thrombosis
Interventions:   Drug: Enoxaparin;   Drug: warfarin;   Drug: Placebo for apixaban;   Drug: Placebo for enoxaparin;   Drug: Placebo for warfarin;   Drug: apixaban
Sponsors:   Bristol-Myers Squibb;   Pfizer
Recruiting - verified October 2009

Condition:   Venous Thrombosis
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer
Recruiting - verified February 2010

Condition:   Pulmonary Arterial Hypertension
Intervention:   Drug: ambrisentan plus sildenafil or tadalafil
Sponsor:   Gilead Sciences
Recruiting - verified March 2010

Condition:   Hypoactive Sexual Desire Disorder
Interventions:   Drug: testosterone gel;   Drug: placebo gel
Sponsor:   BioSante Pharmaceuticals
Recruiting - verified February 2010

Condition:   Sepsis
Interventions:   Drug: Drotrecogin alfa (activated);   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Hypoactive Sexual Desire Disorder
Interventions:   Drug: testosterone gel;   Drug: placebo gel
Sponsor:   BioSante Pharmaceuticals
Recruiting - verified February 2010

Condition:   Infrarenal Abdominal Aortic Aneurysm
Intervention:   Device: Anaconda Stent Graft System
Sponsors:   Terumo CVS;   Vascutek Ltd., Scotland
Recruiting - verified March 2010

Conditions:   Crohn's Disease;   Ulcerative Colitis;   Inflammatory Bowel Diseases
Interventions:   Biological: infliximab;   Drug: conventional systemic agents;   Biological: Biological therapies other than infliximab
Sponsor:   Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010

Conditions:   Preterm Delivery;   Short Cervix;   Short Uterine Cervical Length
Interventions:   Drug: progesterone;   Drug: placebo
Sponsors:   Columbia Laboratories;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified March 2010

Condition:   Breast Tumors
Intervention:   Drug: Trabectedin; ET 743; Yondelis
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   PharmaMar S.A.
Recruiting - verified February 2010

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: flutamide;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Conditions:   Cognitive/Functional Effects;   Metastatic Cancer;   Neurotoxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: memantine hydrochloride;   Other: placebo;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Osteoarthritis
Interventions:   Drug: SD-6010;   Drug: SD-6010;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: samarium Sm 153 lexidronam pentasodium
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Atherosclerosis;   Myocardial Ischemia;   Myocardial Infarction
Interventions:   Drug: SCH 530348;   Drug: Placebo
Sponsors:   Schering-Plough;   Duke University
Recruiting - verified March 2010

Conditions:   Staphylococcus Aureus;   Bacteremia;   Mediastinitis
Interventions:   Biological: V710;   Biological: Comparator: Placebo (unspecified)
Sponsor:   Merck
Recruiting - verified March 2010

Conditions:   Psoriasis;   Arthritis, Psoriatic
Interventions:   Drug: conventional systemic agents;   Biological: infliximab;   Biological: ustekinumab;   Biological: Biological therapies other than infliximab and ustekinumab
Sponsor:   Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Interventions:   Drug: bortezomib, thalidomide, and dexamethasone (VTD);   Drug: bortezomib and dexamethasone (VD);   Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor:   Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010

Condition:   Neuroblastoma
Interventions:   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: topotecan hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Genetic: DNA ploidy analysis;   Genetic: chromosomal translocation analysis;   Genetic: fluorescence in situ hybridization;   Genetic: polymorphism analysis;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Heart Decompensation
Interventions:   Drug: Placebo;   Drug: Nesiritide
Sponsor:   Scios, Inc.
Recruiting - verified February 2010

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: ifosfamide;   Drug: paclitaxel
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Ototoxicity;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Procedure: management of therapy complications
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Anemia;   Chronic Kidney Disease;   Kidney Disease
Interventions:   Drug: darbepoetin alfa QW;   Drug: darbepoetin alfa Q2W
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Thoracic Aortic Aneurysms
Intervention:   Device: Relay Thoracic Stent-Graft
Sponsor:   Bolton Medical
Recruiting - verified March 2010

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Drug: warfarin;   Drug: apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Premature Labor
Interventions:   Drug: Placebo;   Drug: GSK221149A
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: isotretinoin;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Supraventricular Tachycardia in Infants
Intervention:   Drug: digoxin and propranolol
Sponsors:   University of British Columbia;   The Hospital for Sick Children;   University of Utah
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Osteoarthritis
Interventions:   Drug: Celecoxib;   Drug: Any commercially available NSAID with the indication for osteoarthritis
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: gemtuzumab ozogamicin;   Drug: mitoxantrone hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: clofarabine;   Drug: cytarabine;   Drug: methotrexate;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: thioguanine
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   HIV-1
Intervention:   Drug: TMC125
Sponsor:   Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Interventions:   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Other: clinical observation;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Arthritis, Rheumatoid;   Osteoarthritis
Interventions:   Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Sponsors:   Pfizer;   The Cleveland Clinic
Recruiting - verified March 2010

Condition:   Retinoblastoma
Interventions:   Drug: carboplatin;   Drug: etoposide;   Drug: vincristine sulfate;   Other: clinical observation
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Southwest Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Adrenocortical Carcinoma
Interventions:   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: mitotane;   Procedure: conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Head and Neck Cancer;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Drug: CHOP regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Carotid Artery Disease;   Carotid Stenosis;   Stroke;   Atherosclerosis
Interventions:   Device: Carotid artery stenting with filter (interventional);   Procedure: Carotid artery endarterectomy (surgical)
Sponsor:   Abbott Vascular
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Docetaxel;   Biological: cetuximab;   Drug: Pemetrexed
Sponsors:   Eli Lilly and Company;   ImClone LLC
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: lomustine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Genetic: cytogenetic analysis;   Genetic: mutation analysis;   Genetic: polymorphism analysis;   Other: questionnaire administration
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: zoledronic acid;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Southwest Oncology Group;   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer
Interventions:   Biological: bleomycin sulfate;   Drug: cisplatin;   Drug: etoposide;   Procedure: conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010